Organon and MRC Technology sign antibody development agreement
Organon, the human healthcare business unit of Akzo Nobel, together with MRC Technology announced that they have signed a collaborative agreement to develop a humanized antibody for the treatment of certain forms of cancer. The Therapeutic Antibody Group (TAG) at MRCT will use its proprietary CDR grafting technology to generate a humanized clinical candidate from a murine antibody discovered at Organon's Research Center in Cambridge, MA (USA). Organon will pay MRCT research and development milestones, and royalties based on net sales that may result from the commercialization of any antibody products. Organon will retain all development and commercialization rights. Additional financial terms were not disclosed.
"Organon has been stepping up its efforts to discover and develop novel biotherapeutics for oncology and auto-immune disorders. The collaboration with MRCT on its well-validated antibody humanization technology is a further step towards becoming effective biotherapeutic drug hunters," said David Nicholson, EVP of R&D at Organon.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.